Press Releases
Samsung Biologics sales and profits in 2016
Date 24 January 2017
Samsung Biologics Sales and Profits in 2016.
Samsung Biologics improves its performance in sales and operating profit of 2016 with a focus on the contract manufacturing business.
Samsung Biologics said today sales of 2016 reached 294.6 billion won in the first earning report since a successful initial public offering(IPO), Nov. 10 last year.
It posted 30.4 billion won in operating loss. Sales increased 223%, and operating loss improved 85% in 2016 over 2015.
According to the net loss, Samsung Biologics reflected a one-time factor, non-operating income of 2.7 trillion won as a result of revaluation of our 91.2% stake held in Samsung Bioepis in 2015.
The results are mainly affected by two factors below in CMO business.
1) First Plant is fully operating
2) Second Plant started trial production
※ Company’s overall rate of operation has been increased
As SBL's first plant became fully operational for the CMO business and its second plant initiated trial production, Samsung Biologics' sales reached 295.6 billion won, 223 percent increased from the previous year's 91.3 billion won. Also the company's operating loss decreased 30 percent.
Samsung Biologics expects to improve its performance as the first plant will maintain fully operational and the second plant will gradually increase the rate of operation in 2017.
On the other hand, it has completed 60 percent of the construction of its third plant and plans to finish building it by the end of this year.
Once the third plant is finished, it is expected to be the world largest one.
- END -
Date 24 January 2017
Samsung Biologics Sales and Profits in 2016.
Samsung Biologics improves its performance in sales and operating profit of 2016 with a focus on the contract manufacturing business.
Samsung Biologics said today sales of 2016 reached 294.6 billion won in the first earning report since a successful initial public offering(IPO), Nov. 10 last year.
It posted 30.4 billion won in operating loss. Sales increased 223%, and operating loss improved 85% in 2016 over 2015.
According to the net loss, Samsung Biologics reflected a one-time factor, non-operating income of 2.7 trillion won as a result of revaluation of our 91.2% stake held in Samsung Bioepis in 2015.
The results are mainly affected by two factors below in CMO business.
1) First Plant is fully operating
2) Second Plant started trial production
※ Company’s overall rate of operation has been increased
As SBL's first plant became fully operational for the CMO business and its second plant initiated trial production, Samsung Biologics' sales reached 295.6 billion won, 223 percent increased from the previous year's 91.3 billion won. Also the company's operating loss decreased 30 percent.
Samsung Biologics expects to improve its performance as the first plant will maintain fully operational and the second plant will gradually increase the rate of operation in 2017.
On the other hand, it has completed 60 percent of the construction of its third plant and plans to finish building it by the end of this year.
Once the third plant is finished, it is expected to be the world largest one.
- END -